TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource

IF 11.5 2区生物学 Q1 GENETICS & HEREDITY Genomics, Proteomics & Bioinformatics Pub Date : 2023-04-01 DOI:10.1016/j.gpb.2022.08.004

Zhihang Chen , Ziwei Luo , Di Zhang , Huiqin Li , Xuefei Liu , Kaiyu Zhu , Hongwan Zhang , Zongping Wang , Penghui Zhou , Jian Ren , An Zhao , Zhixiang Zuo

{"title":"TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource","authors":"Zhihang Chen , Ziwei Luo , Di Zhang , Huiqin Li , Xuefei Liu , Kaiyu Zhu , Hongwan Zhang , Zongping Wang , Penghui Zhou , Jian Ren , An Zhao , Zhixiang Zuo","doi":"10.1016/j.gpb.2022.08.004","DOIUrl":null,"url":null,"abstract":"<div><p><strong>Immunotherapy</strong> is a promising cancer treatment method; however, only a few patients benefit from it. The development of new immunotherapy strategies and effective <strong>biomarkers</strong> of response and resistance is urgently needed. Recently, high-throughput bulk and single-cell <strong>gene expression</strong> profiling technologies have generated valuable resources. However, these resources are not well organized and systematic analysis is difficult. Here, we present TIGER, a tumor immunotherapy gene expression resource, which contains bulk transcriptome data of 1508 tumor samples with clinical immunotherapy outcomes and 11,057 tumor/normal samples without clinical immunotherapy outcomes, as well as single-cell transcriptome data of 2,116,945 immune cells from 655 samples. TIGER provides many useful modules for analyzing collected and user-provided data. Using the resource in TIGER, we identified a tumor-enriched subset of CD4<sup>+</sup> T cells. Patients with melanoma with a higher signature score of this subset have a significantly better response and survival under immunotherapy. We believe that TIGER will be helpful in understanding anti-tumor immunity mechanisms and discovering effective biomarkers. TIGER is freely accessible at <span>http://tiger.canceromics.org/</span><svg><path></path></svg>.</p></div>","PeriodicalId":12528,"journal":{"name":"Genomics, Proteomics & Bioinformatics","volume":null,"pages":null},"PeriodicalIF":11.5000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genomics, Proteomics & Bioinformatics","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1672022922000997","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 19

Abstract

Immunotherapy is a promising cancer treatment method; however, only a few patients benefit from it. The development of new immunotherapy strategies and effective biomarkers of response and resistance is urgently needed. Recently, high-throughput bulk and single-cell gene expression profiling technologies have generated valuable resources. However, these resources are not well organized and systematic analysis is difficult. Here, we present TIGER, a tumor immunotherapy gene expression resource, which contains bulk transcriptome data of 1508 tumor samples with clinical immunotherapy outcomes and 11,057 tumor/normal samples without clinical immunotherapy outcomes, as well as single-cell transcriptome data of 2,116,945 immune cells from 655 samples. TIGER provides many useful modules for analyzing collected and user-provided data. Using the resource in TIGER, we identified a tumor-enriched subset of CD4⁺ T cells. Patients with melanoma with a higher signature score of this subset have a significantly better response and survival under immunotherapy. We believe that TIGER will be helpful in understanding anti-tumor immunity mechanisms and discovering effective biomarkers. TIGER is freely accessible at http://tiger.canceromics.org/.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

TIGER：肿瘤免疫治疗基因表达资源门户网站。

免疫疗法是一种很有前途的癌症治疗方法；然而，只有少数患者从中受益。迫切需要开发新的免疫治疗策略和有效的反应和耐药性生物标志物。近年来，高通量批量和单细胞基因表达谱技术产生了宝贵的资源。然而，这些资源没有得到很好的组织，很难进行系统的分析。在这里，我们介绍了肿瘤免疫疗法基因表达资源TIGER，它包含1508个具有临床免疫疗法结果的肿瘤样本和11057个没有临床免疫治疗结果的肿瘤/正常样本的大量转录组数据，以及655个样本的2116945个免疫细胞的单细胞转录组数据。TIGER为分析收集的数据和用户提供的数据提供了许多有用的模块。利用TIGER中的资源，我们鉴定了CD4+T细胞的肿瘤富集亚群。该亚群特征得分较高的黑色素瘤患者在免疫治疗下的反应和生存率明显更好。我们相信TIGER将有助于了解抗肿瘤免疫机制和发现有效的生物标志物。TIGER可在http://tiger.canceromics.org/.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Genomics, Proteomics & Bioinformatics Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

14.30

自引率

4.20%

发文量

844

审稿时长

61 days

期刊介绍： Genomics, Proteomics and Bioinformatics (GPB) is the official journal of the Beijing Institute of Genomics, Chinese Academy of Sciences / China National Center for Bioinformation and Genetics Society of China. It aims to disseminate new developments in the field of omics and bioinformatics, publish high-quality discoveries quickly, and promote open access and online publication. GPB welcomes submissions in all areas of life science, biology, and biomedicine, with a focus on large data acquisition, analysis, and curation. Manuscripts covering omics and related bioinformatics topics are particularly encouraged. GPB is indexed/abstracted by PubMed/MEDLINE, PubMed Central, Scopus, BIOSIS Previews, Chemical Abstracts, CSCD, among others.